Clinical trial Golden Gate Study
Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia With Safety Run-in
| Cancers | |
|---|---|
| Organ | Blood |
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Amgen |
| EudraCT Identifier | 2020-004498-29 |
| Inclusion criteria | Phase 3 Randomized, Controlled Study ofBlinatumomab Alternating With Low-intensityChemotherapy Versus Standard of Care forOlder Adults With Newly DiagnosedPhiladelphia-negative B-cell Precursor AcuteLymphoblastic Leukemia With Safety Run-in(Golden G |
| Last update |